The EPO published Patent EP3675852A1 granting Takeda Pharmaceutical Company Limited exclusive rights to soticlestat pharmaceutical compositions for treatment of epileptic encephalopathy. The patent is classified under A61K 31/444 and A61P 25/08, covering the compound's therapeutic application in neurological seizure conditions. Designated states include all current EU member states and extension states.

Pharmaceutical companies and drug manufacturers should review the patent claims to assess potential licensing requirements or competitive landscape implications for epileptic encephalopathy treatments. Legal professionals advising biotech and pharmaceutical clients should evaluate the patent's scope for freedom-to-operate analyses. No immediate compliance actions or deadlines are required as this is an intellectual property grant rather than a regulatory compliance obligation.